Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5V9O

KRAS G12C inhibitor

Summary for 5V9O
Entry DOI10.2210/pdb5v9o/pdb
Related5V9L
DescriptorGTPase KRas, GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, ... (5 entities in total)
Functional Keywordskras mutant inhibitor, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
Biological sourceHomo sapiens (Human)
Cellular locationCell membrane ; Lipid-anchor ; Cytoplasmic side : P01116
Total number of polymer chains1
Total formula weight20274.30
Authors
Westover, K.,Lu, J. (deposition date: 2017-03-23, release date: 2017-08-23, Last modification date: 2024-10-30)
Primary citationZeng, M.,Lu, J.,Li, L.,Feru, F.,Quan, C.,Gero, T.W.,Ficarro, S.B.,Xiong, Y.,Ambrogio, C.,Paranal, R.M.,Catalano, M.,Shao, J.,Wong, K.K.,Marto, J.A.,Fischer, E.S.,Janne, P.A.,Scott, D.A.,Westover, K.D.,Gray, N.S.
Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C.
Cell Chem Biol, 24:1005-1016.e3, 2017
Cited by
PubMed Abstract: Targeted covalent small molecules have shown promise for cancers driven by KRAS G12C. Allosteric compounds that access an inducible pocket formed by movement of a dynamic structural element in KRAS, switch II, have been reported, but these compounds require further optimization to enable their advancement into clinical development. We demonstrate that covalent quinazoline-based switch II pocket (SIIP) compounds effectively suppress GTP loading of KRAS G12C, MAPK phosphorylation, and the growth of cancer cells harboring G12C. Notably we find that adding an amide substituent to the quinazoline scaffold allows additional interactions with KRAS G12C, and remarkably increases the labeling efficiency, potency, and selectivity of KRAS G12C inhibitors. Structural studies using X-ray crystallography reveal a new conformation of SIIP and key interactions made by substituents located at the quinazoline 2-, 4-, and 7-positions. Optimized lead compounds in the quinazoline series selectively inhibit KRAS G12C-dependent signaling and cancer cell growth at sub-micromolar concentrations.
PubMed: 28781124
DOI: 10.1016/j.chembiol.2017.06.017
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.56 Å)
Structure validation

229183

PDB entries from 2024-12-18

PDB statisticsPDBj update infoContact PDBjnumon